Parkside Financial Bank & Trust’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.86K Hold
189
– – ﹤0.01% 1900
2026
Q1
$3.63K Hold
189
– – ﹤0.01% 1920
2025
Q4
$3.12K Hold
189
– – ﹤0.01% 1953
2025
Q3
$2.75K Buy
189
+39
+26% +$560 ﹤0.01% 1909
2025
Q2
$2.1K Buy
+150
New +$2.11K ﹤0.01% 1986

Other funds holding DNLI

Parkside Financial Bank & Trust's DNLI Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 189 shares worth $4.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

Parkside Financial Bank & Trust first reported a position in DNLI in Q2 2025 and has held it in 5 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Parkside Financial Bank & Trust held 189 shares of Denali Therapeutics worth $4.86K as of Q2 2026.
  • Parkside Financial Bank & Trust left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1900 holding.
  • Parkside Financial Bank & Trust first reported a position in Denali Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.